Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Apr;6(2):139-151.
doi: 10.2217/cns-2016-0038.

Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine

Tyler Lazaro  1   2 , Priscilla K Brastianos  1   2
Affiliations
Review

Immunotherapy and targeted therapy in brain metastases: emerging options in precision medicine

Tyler Lazaro et al. CNS Oncol. 2017 Apr.

Abstract

Brain metastases (BM) continue to represent an unmet clinical need in oncology. Immunotherapy and targeted therapy hold great promise in the treatment of BM. Emerging data are confirming the activity of these agents in patients with BM. Genomic studies have confirmed that clinically actionable mutations are present in BM and they can be used in clinical studies to link targeted therapies with their genetic targets. Furthermore, as molecular signatures associated with sensitivity and resistance to immunotherapies are developed, we will better be able to select BM patients who will most benefit from these therapies. Understanding the genetic and immune evolution within BM should drive the next generation of immunotherapy and target therapy, as well as increase the accuracy of the selection process for these therapies.

Keywords: brain metastases; genomics; immunotherapy; targeted therapy.

PubMed Disclaimer

Conflict of interest statement

Financial & competing interests disclosure

PK Brastianos has consulted for Angiochem and Genentech and has received honoraria from Merck and Genentech. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

References

    1. Schouten LJ, Rutten J, Huveneers HAM, Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer. 2002;94(10):2698–2705. - PubMed
    1. Clouston PD, DeAngelis LM, Posner JB. The spectrum of neurological disease in patients with systemic cancer. Ann. Neurol. 1992;31(3):268–273. - PubMed
    1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE. Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the Metropolitan Detroit Cancer Surveillance System. J. Clin. Oncol. 2004;22(14):2865–2872. - PubMed
    1. Posner JB, Chernik NL. Intracranial metastases from systemic cancer. Adv. Neurol. 1978;19:579–592. - PubMed
    1. Soffietti R, Rudā R, Mutani R. Management of brain metastases. J. Neurol. 2002;249(10):1357–1369. - PubMed

LinkOut - more resources